Netabolics

Ready to see how your drug targets transform cell biology in real-time? Join us at BioTechX Europe 2024! Next week in Basel Mauro DiNuzzo will showcase our cutting-edge biosimulation technology, and you’ll have the chance to test-drive a demo version of our software. Imagine manipulating thousands of gene-associated reactions and watching thousands of molecular species respond, all in seconds. This is the future of AI-driven #biosimulation for #drugdiscovery. Want to connect? Reach out to Mauro and let’s accelerate innovation together! Our participation to #BioTechX is supported by the European Regional Development Fund through the Coesione Italia 21-27 program of Regione Lazio and Lazio Innova. #techbio #artificialintelligence #multiomics

#RExPO24 Day 2 | Session 3: Anti-effective and anti-cancer chemotherapy Why does it take so long for #ScientificInnovation to reach #CancerPatients? This was one of the key questions addressed during this session, where 4 international speakers from different professional and academic backgrounds explored current existing challenges in #Oncology to develop therapies in a cost effective and timely manner. To address the crucial need of finding alternative routes for the development of #medicines, some of the speakers also highlighted how they’re taking novel approaches by leveraging biological knowledge, multi-omics data and artificial intelligence. The result? AI-powered platforms capable of providing a robust framework for #DrugRepurposing in #Cancer. This session featured 4 talks 👇 💊 ’Antibiotics resistance: Meet the challenge’ by Hannelore Meyer (Technical University of Munich) 💊 ’The challenge of translation: Reflections of a cancer patient-scientist’ by Anneke Blackburn (The Australian National University) 💊 ’Targeting signalling modules in thyroid cancer’ by Prashant Changoer (Radboudumc) 💊 ’Biosimulation-based target deconvolution of cancer metabolism’ by Mauro DiNuzzo (Netabolics) If you want to learn more about each topic covered in this session, visit the RExPO24 Abstract Collection on Drug Repurposing Central, curated via ScienceOpen ➡ https://lnkd.in/eTn7upU8 🇪🇺 #EUfunded #H2020 #FutureOfMedicine #FutureOfHealthcare #AIinMedicine

We’re back with another weekly roundup 🌟 Here's what's making waves this week: 🚀 𝐅𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐁𝐢𝐨 𝐒𝐞𝐜𝐮𝐫𝐞𝐬 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 𝐁𝐨𝐨𝐬𝐭 This $372m investment, led by Andreessen Horowitz and supported by Sanofi, will accelerate their mission to revolutionize clinical trials and drug development processes. https://lnkd.in/e9DuKS86  🧬 𝐄𝐥𝐢 𝐋𝐢𝐥𝐥𝐲 𝐉𝐨𝐢𝐧𝐬 𝐅𝐨𝐫𝐜𝐞𝐬 𝐰𝐢𝐭𝐡 𝐎𝐩𝐞𝐧𝐀𝐈 𝐭𝐨 𝐂𝐨𝐦𝐛𝐚𝐭 𝐀𝐌𝐑  This collaboration aims to fast-track the discovery of new treatments against drug-resistant pathogens, marking a significant step in global health innovation.  https://lnkd.in/eNzHxw7A  🏥 𝐌𝐚𝐬𝐬 𝐆𝐞𝐧𝐞𝐫𝐚𝐥 𝐁𝐫𝐢𝐠𝐡𝐚𝐦'𝐬 𝐀𝐈 𝐒𝐩𝐞𝐞𝐝𝐬 𝐔𝐩 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬 𝐄𝐧𝐫𝐨𝐥𝐦𝐞𝐧𝐭 Using OpenAI’s GPT-4, they achieved up to 100% accuracy in identifying eligible patients for a heart failure study, dramatically cutting costs to just 11 cents per patient. https://lnkd.in/gfD3gha6  🌟 𝐀𝐈-𝐃𝐫𝐢𝐯𝐞𝐧 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐒𝐮𝐦𝐦𝐢𝐭 𝐍𝐞𝐰𝐬 🌟 🤝 𝐇𝐆𝐅 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐦𝐞𝐧𝐭: We're thrilled to partner with HGF Limited! Join Dr. Lauris Kemp, Partner & Patent Attorney, as she discusses navigating IP considerations within AI drug discovery. 🔬 𝐓𝐞𝐜𝐡 𝐓𝐞𝐬𝐭 𝐋𝐚𝐛 Launch Success: Our All-New Tech Test Lab is proud to feature its first exhibitor: Netabolics! This deep tech startup specializes in advanced in silico solutions for drug discovery, integrating AI and mechanistic biosimulation to empower pharmaceutical R&D. Their mission? Transforming drug development by predicting drug behaviour and optimizing efficacy early in the process.  Stay tuned for more updates and insights at the AI-Driven Drug Discovery Summit!

We are happy to announce that Mauro DiNuzzo, Alessandro Scandurra, and Marco Salvatore, PhD, will be presenting new results and showcasing our technology at the upcoming RExPO24 conference, taking place from 3rd to 5th July in Munich, Germany. Mark your calendars for July 4th at 11am, as Mauro takes the stage to discuss "Biosimulation-based target deconvolution of cancer metabolism". For a sneak peek, check out the abstract published on ScienceOpen: https://lnkd.in/dSrZZahb Don't forget to explore the full agenda of RExPO24 on their website: https://lnkd.in/eHkdjEGv See you in Munich! #Oncology #CancerResearch #CancerMetabolism #ArtificialIntelligence #CombinationTherapy #TargetDeconvolution #RExPO24 #Netabolics

Introducing our first start-ups for BioTechX Europe 2024 🥳 BioTechX Europe 2024 will host 50 start-ups from across the biotech and genomics space, working on working on cutting-edge innovative platform technologies and pioneering AI and machine learning solutions. Alva Genomics 38 Labs Calico Biosystems CompagOs Hygiaso AG Doppl SA iLoF Netabolics Orbits Oncology QP Mind molab.ai ENHANC3D GENOMICS Turing Biosystems OmicsChart (Techstars'23) Exazyme THT Biomaterials GmbH Transmineo Ourobionics IMIDeology Arachne.ai TMA Precision Health Interested in joining these start-ups at BioTechX EU? Contact Asad Javed 📧 Asad.Javed@terrapinn.com Learn more here 👉🏻 https://lnkd.in/ewZfWr5b

Announcing our first batch of Start-ups joining us at #BioTechX at the Basel Congress Center this October 9-10th!!!! 🚀 If theres one thing people love more than a cup of tea with some custard creams on a saturday morning 🍵 (or scones if you're feeling fancy), its meeting start-ups within the life science industry! We know the importance of putting upcoming Start-ups infront of Tech Execs from small to big pharma, to not only raise their company profile and help them develop new partnerships but also help drive change within the life science industry. Develop new Partnerships with Investors, Biotech firms and Pharma ✅ Connect with over 3000 Healthcare Professionals ✅ Revolutionize the Industry ✅ If you are a Start-up who is interested, do email me below or alternatively book a call using the link on my profile! 📧 asad.javed@terrapinn.com